ArticleCancer biology & therapy2014

RAD50 targeting impairs DNA damage response and sensitizes human breast cancer cells to cisplatin therapy.

Ali Flores-Pérez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.